Results 201 to 210 of about 159,423 (276)

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

open access: yesMolecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris   +10 more
wiley   +1 more source

The concurrent silencing of Tim-3 and STAT-3 promotes tumor regression both in vitro and in ovo. [PDF]

open access: yesBMC Cancer
Karami R   +9 more
europepmc   +1 more source

TIM-3 polimorfizmlerinin astım hastalığı ile ilişkisi

open access: yes, 2007
Yakın bir zamanda, Th1 hücre yüzeyinde TIM gen ailesine ait olan Tim-3 adında yeni bir reseptör tanımlanmış ve bu molekülün etkisinin Th1 yönetimli immün yanıtlar üzerine olduğu bildirilmiştir. Bu reseptörün, T lenfositlerde eksprese edilen Galectin-9 adlı ligandı ile etkileşimi sonucunda efektör Th1 hücrelerinin eliminasyonuna neden olduğu ve ...
openaire   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance. [PDF]

open access: yesCell Commun Signal
Zamani P   +6 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. [PDF]

open access: yesJ Immunother Cancer
Ghiringhelli F   +23 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy